Suggested remit - To appraise the clinical and cost effectiveness of siponimod within its marketing authorisation for treating secondary progressive multiple sclerosis in adults
|
Status
|
In progress
|
| Process |
STA 2018
|
| ID number |
1304
|
Provisional Schedule
| Committee meeting: 1 |
12 March 2020 |
| Expected publication |
03 June 2020 |
Project Team
Email enquiries
| Evidence Review Group / Assessment Group |
Warwick Evidence, Warwick Medical School, University of Warwick |
Consultees
| Companies sponsors |
Novartis (siponimod) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Multiple Sclerosis Society |
| |
Multiple Sclerosis Trust |
| Professional groups |
Association of British Neurologists |
| |
Royal College of Physicians |
| |
UK Clinical Pharmacy Association |
| |
UK Multiple Sclerosis Specialist Nurse Association |
Commentators
| Comparator companies |
Novartis (interferon beta 1b) |
| |
Bayer (interferon beta 1b) - (confidentiality agreement not signed, not participating) |
| |
Biogen (dimethyl fumarate, interferon beta 1a) |
| |
Merck (interferon beta 1a) (confidentiality agreement not signed, not participating) |
| |
Mylan (glatiramer acetate) (confidentiality agreement not signed, not participating) |
| |
Roche (ocrelizumab) (confidentiality agreement not signed, not participating) |
| |
Sanofi Genzyme (teriflunomide) |
| |
Teva (glatiramer acetate(confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
|
Date
|
Update
|
|
16 July 2019
|
Invitation to participate |
|
16 July 2019
|
In progress, Appraisal has been referred to NICE. |
|
20 November 2018 - 18 December 2018
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance